141 related articles for article (PubMed ID: 23052169)
1. Mutational and expressional analyses of NRF2 and KEAP1 in sarcomas.
Je EM; An CH; Yoo NJ; Lee SH
Tumori; 2012; 98(4):510-5. PubMed ID: 23052169
[TBL] [Abstract][Full Text] [Related]
2. [An analysis of autopsy cases of malignant soft tissue and bone tumors].
Enjoji M; Hashimoto H; Yamamoto I; Daimaru Y
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-3):1931-6. PubMed ID: 2543328
[TBL] [Abstract][Full Text] [Related]
3. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Je EM; An CH; Yoo NJ; Lee SH
APMIS; 2012 Aug; 120(8):635-9. PubMed ID: 22779686
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations of the KEAP1 gene in common solid cancers.
Yoo NJ; Kim HR; Kim YR; An CH; Lee SH
Histopathology; 2012 May; 60(6):943-52. PubMed ID: 22348534
[TBL] [Abstract][Full Text] [Related]
6. Expression of the Nrf2 and Keap1 proteins and their clinical significance in osteosarcoma.
Zhang J; Wang X; Wu W; Dang H; Wang B
Biochem Biophys Res Commun; 2016 Apr; 473(1):42-46. PubMed ID: 26987716
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
8. Current molecular and therapeutic advances in liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, and angiosarcoma.
Tanriverdi O; Yildiz A
J Oncol Pharm Pract; 2022 Apr; 28(3):635-645. PubMed ID: 35043739
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.
Mertens F; Fletcher CD; Dal Cin P; De Wever I; Mandahl N; Mitelman F; Rosai J; Rydholm A; Sciot R; Tallini G; Van den Berghe H; Vanni R; Willén H
Genes Chromosomes Cancer; 1998 May; 22(1):16-25. PubMed ID: 9591630
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K; Motohashi H; Yamamoto M
Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
[TBL] [Abstract][Full Text] [Related]
12. Acetyl-l-carnitine prevents homocysteine-induced suppression of Nrf2/Keap1 mediated antioxidation in human lens epithelial cells.
Yang SP; Yang XZ; Cao GP
Mol Med Rep; 2015 Jul; 12(1):1145-50. PubMed ID: 25776802
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.
Lister A; Nedjadi T; Kitteringham NR; Campbell F; Costello E; Lloyd B; Copple IM; Williams S; Owen A; Neoptolemos JP; Goldring CE; Park BK
Mol Cancer; 2011 Apr; 10():37. PubMed ID: 21489257
[TBL] [Abstract][Full Text] [Related]
14. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival.
Wong TF; Yoshinaga K; Monma Y; Ito K; Niikura H; Nagase S; Yamamoto M; Yaegashi N
Int J Gynecol Cancer; 2011 Nov; 21(8):1428-35. PubMed ID: 21897267
[TBL] [Abstract][Full Text] [Related]
15. Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy.
Zhong Q; Mishra M; Kowluru RA
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3941-8. PubMed ID: 23633659
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of the Nrf2-Keap1 signaling pathway in cancer.
Jaramillo MC; Zhang DD
Genes Dev; 2013 Oct; 27(20):2179-91. PubMed ID: 24142871
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study of the Nrf2 pathway in colorectal cancer: Nrf2 expression is closely correlated to Keap1 in the tumor and Bach1 in the normal tissue.
Chang LC; Fan CW; Tseng WK; Chen JR; Chein HP; Hwang CC; Hua CC
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):511-7. PubMed ID: 23455180
[TBL] [Abstract][Full Text] [Related]
19. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
Hayes JD; McMahon M
Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
[TBL] [Abstract][Full Text] [Related]
20. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
